Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial

Compared with epirubicin, idarubicin increased survival rates in participants with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization without an increase adverse event incidence.